Heroin Dependence, Opioid-Related Disorders, Substance-Related Disorders
Conditions
Keywords
heroin, opioid disorders, substance related disorders
Brief summary
The purpose of this study is to evaluate the effects of treatment medications (methadone, buprenorphine, LAAM, naltrexone, naltrexone microcapsules, and methoclocinnamox) on I.V. and smoked heroin self-administration.
Detailed description
Abuse of prescription opioid medications has increased dramatically in the U.S. during the past decade, as indicated by a variety of epidemiological sources. However, few studies have systematically examined the relative reinforcing effects of commonly abused opioid medications. The current inpatient study was designed to compare the effects of intravenously delivered fentanyl , oxycodone, morphine, buprenorphine and heroin in morphine-maintained heroin abusers. All of the participants received all of the drugs tested; drugs and doses were administered in non-systematic order.
Interventions
DRUGopiates
prescription opioids
Sponsors
National Institute on Drug Abuse (NIDA)
New York State Psychiatric Institute
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 45 Years
Healthy volunteers
No
Inclusion criteria
Inclusion Criterion 1. DSM IV criteria for opioid dependence 2. No major mood, psychotic, or anxiety disorder 3. Physically healthy 4. Able to perform study procedures 5. 21-45 years of age 6. Current use of i.v. heroin in amounts/frequencies 7. Not seeking treatment for opioid dependence Exclusion Criterion 1. DSM IV criteria for dependence on drugs other 2. Participants requesting treatment 3. Participants on parole or probation 4. Pregnancy or lactation 5. Birth, miscarriage or abortion with 6 months 6. Recent history of or current significant violent behavior 7. Current major Axis I psychopathology, other than heroin dependence ( e.g., mood disorder with functional impairment or suicide risk, schizophrenia), which might interfere with ability to participate in the study 8. Hepatitis with SGOT or SGPT \> 3 times normal 9. Significant suicide risk 10. Current or history of chronic pain 11. Sensitivity, allergy, or contraindication to opioids
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Amount drug self-administered | 90 minutes | All of the participants received all of the drugs tested; drugs and doses were administered in non-systematic order. Participants were instructed to choose between the dose that they had received during the sample session or another reward.. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Subjective responses | 90 min | Four questionnaires were used to assess subjective effects |
Countries
United States
Outcome results
None listed